Nicolas Deleval1,2, Louise Pesque1,2, Arnaud Dieudonné1, Flore Viry3, Olivia Hentic4, Rachida Lebtahi1,2, Philippe Ruszniewski2,4,5, Louis de Mestier6,7,8. 1. Department of Nuclear Medicine, ENETS Centre of Excellence, Beaujon Hospital (APHP), Clichy, France. 2. Université de Paris, Paris, France. 3. Department of Radiology, Lariboisière Hospital (APHP), Paris, France. 4. Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon Hospital (APHP), 100 boulevard du Général Leclerc, 92110, Clichy, France. 5. INSERM U1149, Centre of Research in Inflammation, Beaujon Hospital, Clichy, France. 6. Université de Paris, Paris, France. louis.demestier@aphp.fr. 7. Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon Hospital (APHP), 100 boulevard du Général Leclerc, 92110, Clichy, France. louis.demestier@aphp.fr. 8. INSERM U1149, Centre of Research in Inflammation, Beaujon Hospital, Clichy, France. louis.demestier@aphp.fr.
Abstract
OBJECTIVES: Bone metastases (BM) may influence negatively the prognosis of midgut neuroendocrine tumors (NET). The diagnostic sensitivity of 18F-DOPA PET for midgut NET and associated metastases is high. This study aimed to assess the prognostic impact of BM detected by 18F-DOPA PET in metastatic midgut NET. METHODS: All patients with a metastatic midgut NET, who underwent a 18F-DOPA PET between June 2011 and June 2018, were included. BM were defined following imaging criteria and were classified as poly-BM or oligo-BM, according to their number (< 5 or ≥ 5, respectively). The variables associated with the presence of BM were evaluated by logistic regression. The factors associated with overall survival were explored by Cox regression models. RESULTS: Among 155 patients included, 46 had BM (29.7%). A carcinoid syndrome (OR 2.96, p = 0.009) and ≥ 3 extra-skeletal metastatic organs (OR 4.99, p = 0.002) were independently associated with the presence of BM. BM were mainly osteoblastic (78%), rarely symptomatic (8.9%), and had a short-term therapeutic impact for 3 patients (6.5%). The presence of BM (HR 2.67, p = 0.034), older age (HR 1.07, p = 0.016), and higher Ki67 (HR 1.09, p = 0.025) were independent prognostic factors. Unlike poly-BM (HR 1.92, p = 0.007), oligo-BM was not a poor prognosis factor (HR 0.77, p = 0.699) compared to the group without BM. CONCLUSION: 18F-DOPA PET frequently detects BM in patients with metastatic midgut NET. BM have a negative prognostic impact, especially poly-BM. Conversely, oligo-BM do not influence the prognosis and may not impact therapeutic decisions. KEY POINTS: • 18F-DOPA PET detected bone metastases in 46 (29.7%) of 155 patients with metastatic midgut neuroendocrine tumors. • Bone metastases have a negative prognostic impact in metastatic midgut neuroendocrine tumors. • Bone oligo-metastases (< 5) do not influence the prognosis and may not impact therapeutic decisions.
OBJECTIVES: Bone metastases (BM) may influence negatively the prognosis of midgut neuroendocrine tumors (NET). The diagnostic sensitivity of 18F-DOPA PET for midgut NET and associated metastases is high. This study aimed to assess the prognostic impact of BM detected by 18F-DOPA PET in metastatic midgut NET. METHODS: All patients with a metastatic midgut NET, who underwent a 18F-DOPA PET between June 2011 and June 2018, were included. BM were defined following imaging criteria and were classified as poly-BM or oligo-BM, according to their number (< 5 or ≥ 5, respectively). The variables associated with the presence of BM were evaluated by logistic regression. The factors associated with overall survival were explored by Cox regression models. RESULTS: Among 155 patients included, 46 had BM (29.7%). A carcinoid syndrome (OR 2.96, p = 0.009) and ≥ 3 extra-skeletal metastatic organs (OR 4.99, p = 0.002) were independently associated with the presence of BM. BM were mainly osteoblastic (78%), rarely symptomatic (8.9%), and had a short-term therapeutic impact for 3 patients (6.5%). The presence of BM (HR 2.67, p = 0.034), older age (HR 1.07, p = 0.016), and higher Ki67 (HR 1.09, p = 0.025) were independent prognostic factors. Unlike poly-BM (HR 1.92, p = 0.007), oligo-BM was not a poor prognosis factor (HR 0.77, p = 0.699) compared to the group without BM. CONCLUSION:18F-DOPA PET frequently detects BM in patients with metastatic midgut NET. BM have a negative prognostic impact, especially poly-BM. Conversely, oligo-BM do not influence the prognosis and may not impact therapeutic decisions. KEY POINTS: • 18F-DOPA PET detected bone metastases in 46 (29.7%) of 155 patients with metastatic midgut neuroendocrine tumors. • Bone metastases have a negative prognostic impact in metastatic midgut neuroendocrine tumors. • Bone oligo-metastases (< 5) do not influence the prognosis and may not impact therapeutic decisions.
Entities:
Keywords:
18F-DOPA PET; Bone metastases; Neuroendocrine tumors; Prognosis; Small intestine
Authors: Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar Journal: Neuroendocrinology Date: 2012-02-15 Impact factor: 4.914
Authors: Wim G Meijer; Eveline van der Veer; Piet L Jager; Erik J van der Jagt; Bert A Piers; Ido P Kema; Elisabeth G E de Vries; Pax H B Willemse Journal: J Nucl Med Date: 2003-02 Impact factor: 10.057
Authors: Klaas P Koopmans; Oliver C Neels; Ido P Kema; Philip H Elsinga; Wim J Sluiter; Koen Vanghillewe; Adrienne H Brouwers; Pieter L Jager; Elisabeth G E de Vries Journal: J Clin Oncol Date: 2008-03-20 Impact factor: 44.544
Authors: Alexander Becherer; Monica Szabó; Georgios Karanikas; Patrick Wunderbaldinger; Peter Angelberger; Markus Raderer; Amir Kurtaran; Robert Dudczak; Kurt Kletter Journal: J Nucl Med Date: 2004-07 Impact factor: 10.057
Authors: Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao Journal: JAMA Oncol Date: 2017-10-01 Impact factor: 31.777
Authors: Katherine Van Loon; Li Zhang; Jennifer Keiser; Cendy Carrasco; Katherine Glass; Maria-Teresa Ramirez; Sarah Bobiak; Eric K Nakakura; Alan P Venook; Manisha H Shah; Emily K Bergsland Journal: Endocr Connect Date: 2014-11-27 Impact factor: 3.335
Authors: Maxime Lelièvre; Elizabeth Katherine Anna Triumbari; Hedia Brixi; Marine Perrier; Guillaume Cadiot; Sophie Deguelte; David Morland Journal: Endocrine Date: 2022-10-07 Impact factor: 3.925